04:45 AM EDT, 06/23/2025 (MT Newswires) -- Exelixis ( EXEL ) said Sunday its phase 3 Stellar-303 trial showed a "statistically significant" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.

The survival rate improvement was observed across all randomized participants compared with regorafenib, the company said.

No new safety issues were identified, and the safety profiles of the combination matched prior data, Exelixis ( EXEL ) said.

The trial will now move to the final analysis of overall survival in the subgroup of patients without liver metastases, the company said.

Shares of Exelixis ( EXEL ) gained 12% in premarket activity Monday.